المؤلفون: Negar Khalili, Mohamad Amin Pourhoseingholi, Ilad Alavi Darazam, Azam Soleymaninia, Latif Gachkar, Akram Hoseyni Kusha, Mohammad Mahdi Rabiei, Minoosh Shabani, Legha Lotfollahi, Mahdi Amirdosara, Firouze Hatami, Parham Torabinavid, Omid Moradi, Mohammadreza Hajiesmaeili, Ali Khoshkar, Masoud Mardani, Hadiseh Shabanpour Dehbsneh, Maryam Taleb Shoushtari, Omidvar Rezaei, Seyed Sina Naghibi Irvani, Shervin Shokouhi, Farid Javandoust Gharehbagh

المصدر: International Immunopharmacology

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Indoles, Immunology, Population, Antiviral Agents, Article, Lopinavir, law.invention, Shahid, COVID-2019, Coronavirus Disease 2019, Randomized controlled trial, law, Informed consent, Internal medicine, medicine, Immunology and Allergy, Humans, education, TTCI, Time to clinical improvement, Aged, Pharmacology, education.field_of_study, Ritonavir, Umifenovir, business.industry, SARS-CoV-2, LFT, liver function test, Arbidol, Hazard ratio, COVID-19, Middle Aged, ABG, Atrial blood gas, COVID-19 Drug Treatment, Clinical trial, SARS-CoV-2, severe acute respiratory syndrome coronavirus2, ICU, Intensive care unit, HR, Hazard Ratio, GCS, Glasgow Coma Scale, Drug Therapy, Combination, Female, business, VBG, Venous blood gas, Interferon beta-1a, medicine.drug, Hydroxychloroquine

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de0a469b2ff51e1cb6c0120853acba1f
http://europepmc.org/articles/PMC8270750